123 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
(atogepant) to prevent chronic and episodic migraine. The overall long-term safety results were consistent with the known safety profile of Qulipta … in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcomes, including
424B5
ABBV
Abbvie Inc
26 Feb 24
Prospectus supplement for primary offering
6:12am
(moderate to severe)
North America, European Union
Plaque psoriasis (moderate to severe chronic)
North America, European Union
Juvenile idiopathic arthritis … separate designations. Imbruvica currently is approved for the treatment of adult patients with blood cancers such as chronic lymphocytic leukemia (“CLL
424B5
j19vxeez0nzk9yudyc
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
znpyei4qau9 qk3h
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
l06g5pw5
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
zoiw191zvslke76dg
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
EX-99.1
21v6ez 73qxgkylisoc
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am
8-K
EX-99.1
s7u5n8f4plt0g2g wa
29 Jul 22
AbbVie Reports Second-Quarter 2022 Financial Results
7:49am
8-K
EX-99.1
lve3y1qwp rck3rj
29 Apr 22
AbbVie Reports First-Quarter 2022 Financial Results
9:00am
8-K
EX-99.1
3op305f
29 Apr 22
AbbVie Reports First-Quarter 2022 Financial Results
7:45am